A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC)
Latest Information Update: 15 Dec 2023
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms ABACO
- 24 Oct 2023 Results of exploratory biomarkers analysis (N=33) presented at the 48th European Society for Medical Oncology Congress.
- 01 Jul 2023 Primary endpoint has been met according to results patients presented at the 25th World Congress on Gastrointestinal Cancer.
- 01 Jul 2023 Status changed from recruiting to completed according to results patients presented at the 25th World Congress on Gastrointestinal Cancer.